Joseph D. McCracken

TL;DR: Five patients relapsed in the brain, all associated with chest failure, and quality control analysis, including dosimetric reconstruction and port film review was introduced after the protocol was activated and was retrospectively applied.

TL;DR: The response rate produced is minimally superior to recent cooperative group studies of colorectal cancer, but the response rate and survival experience are within the range of experience for treatment with 5-FU alone.

TL;DR: Results show that continuous CMFVP is superior to intermittent L‐PAM in decreasing recurrences and increasing survival in both pre‐ and postmenopausal women with operable breast cancer with histologically involved axillary nodes.

TL;DR: There is no indication, except possibly in one very small subset, that the addition of immunotherapy to chemotherapy provides an improvement in OS or in RFS, and significant evidence that chemotherapy alone or chemoimmunotherapy improves OS or RFS when contrasted to outcomes obtained by patients on the control arm.

TL;DR: Regression analysis demonstrated that performance status was the most important pretreatment characteristic for predicting survival in both tumors and neither 5 FU infusion combination appears to significantly alter the dismal prognosis of advanced upper gastrointestinal neoplasms.